Does Sivextro Treat Skin Infections?
No, Sivextro (tedizolid phosphate) does not treat skin infections. The FDA approves it solely for acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including MRSA, but only in patients aged 12 and older.[1] It targets specific pathogens like Staphylococcus aureus and Streptococcus pyogenes, administered intravenously or orally for 6 days.
What Exactly Is Sivextro Approved For?
Sivextro treats ABSSSI, which includes cellulitis, wound infections, and major abscesses. Approval came in 2014 based on phase 3 trials showing non-inferiority to linezolid, with fewer gastrointestinal side effects.[1][2] It does not cover Gram-negative bacteria, fungal, or viral skin conditions.
How Does It Compare to Linezolid for Skin Infections?
Sivextro works like linezolid by inhibiting bacterial protein synthesis, but requires shorter treatment (6 vs 10-14 days) and once-daily dosing. Trials (ESTABLISH-1 and -2) enrolled over 1,200 ABSSSI patients, with Sivextro achieving 92-98% cure rates vs 90-95% for linezolid.[2] It's reserved for cases where other antibiotics fail due to its high cost and IV option.
Common Side Effects in Skin Infection Patients
Patients report nausea (8%), headache (6%), diarrhea (4%), and vomiting (3%). Rare risks include myelosuppression with prolonged use and Clostridium difficile colitis. No unique skin-related adverse effects beyond injection-site reactions.[1]
When Do Patents on Sivextro Expire?
Merck holds key U.S. patents until 2027-2036, covering the compound and formulations. No generics approved yet; check DrugPatentWatch.com for challenges and Paragraph IV filings.[3]
[1]: FDA Label for Sivextro (tedizolid phosphate). https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf
[2]: Prokocimer P et al. N Engl J Med. 2013. https://www.nejm.org/doi/full/10.1056/NEJMoa1300032
[3]: DrugPatentWatch.com - Tedizolid Phosphate Patents. https://www.drugpatentwatch.com/p/tradename/SIVEXTRO